Payment overview · 2025
General Payments
$244.63
5 reported records · 4 companies
Healthcare provider profile · identity verified
Hardeep Mundh
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LIVE OAK, CA · NPI 1982186508
Verified facts
What the public records show
CMS Open Payments records show Hardeep Mundh received $244.63 in general payments during 2025 across 5 reported records.
Neurocrine BioSciences, Inc. accounted for 48.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 479 claims for Eliquis by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $118.74 | 48.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $68.80 | 28.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.65 | 15.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.44 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $244.63 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $118.74 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $68.80 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.65 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $20.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
479 | 51 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
77 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 701 | 121 |
| Furosemide | Furosemide | 637 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 497 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 489 | 99 |
| Eliquis | Apixaban | 479 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 455 | 131 |
| Metformin Hcl | Metformin Hcl | 443 | 83 |
| Gabapentin | Gabapentin | 359 | 71 |
| Potassium Chloride | Potassium Chloride | 347 | 75 |
| Spironolactone | Spironolactone | 326 | 57 |
| Quetiapine Fumarate | Quetiapine Fumarate | 320 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 320 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 291 | 55 |
| Lisinopril | Lisinopril | 289 | 46 |
| Mirtazapine | Mirtazapine | 273 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 258 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 253 | 52 |
| Buspirone Hcl | Buspirone Hcl | 221 | 39 |
| Donepezil Hcl | Donepezil Hcl | 213 | 38 |
| Trazodone Hcl | Trazodone Hcl | 202 | 44 |
| Losartan Potassium | Losartan Potassium | 182 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 43 |
| Lorazepam | Lorazepam | 171 | 59 |
| Tramadol Hcl | Tramadol Hcl | 165 | 77 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 29 |
| Carvedilol | Carvedilol | 159 | 31 |
| Xarelto | Rivaroxaban | 155 | 20 |
| Meloxicam | Meloxicam | 148 | 31 |
| Sertraline Hcl | Sertraline Hcl | 146 | 22 |
| Jardiance | Empagliflozin | 144 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 21 |
| Latanoprost | Latanoprost | 138 | 32 |
| Divalproex Sodium | Divalproex Sodium | 133 | 31 |
| Famotidine | Famotidine | 131 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 130 | 21 |
| Memantine Hcl | Memantine Hcl | 130 | 27 |
| Baclofen | Baclofen | 129 | 26 |
| Midodrine Hcl | Midodrine Hcl | 127 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 116 | 16 |
| Xtampza Er | Oxycodone Myristate | 114 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 107 | 41 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 103 | 18 |
| Alendronate Sodium | Alendronate Sodium | 102 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 100 | 23 |
| Finasteride | Finasteride | 99 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 18 |
| Prednisone | Prednisone | 92 | 32 |
| Risperidone | Risperidone | 91 | 23 |
| Allopurinol | Allopurinol | 90 | 19 |
| Pregabalin | Pregabalin | 90 | 32 |
| Olanzapine | Olanzapine | 89 | 23 |
| Simvastatin | Simvastatin | 88 | 18 |
| Levetiracetam | Levetiracetam | 87 | 12 |
| Myrbetriq | Mirabegron | 87 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 20 |
| Propranolol Hcl | Propranolol Hcl | 82 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 80 | 14 |
| Rexulti | Brexpiprazole | 77 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 16 |
| Aripiprazole | Aripiprazole | 69 | 21 |
| Omeprazole | Omeprazole | 69 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 24 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 68 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 65 | 15 |
| Topiramate | Topiramate | 63 | suppressed |
| Tradjenta | Linagliptin | 61 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 60 | suppressed |
| Glipizide | Glipizide | 60 | 12 |
| Nystatin | Nystatin | 59 | 24 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 59 | 11 |
| Glimepiride | Glimepiride | 57 | suppressed |
| Methadone Hcl | Methadone Hcl | 57 | 26 |
| Bupropion Xl | Bupropion Hcl | 55 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 54 | 17 |
| Hysingla Er | Hydrocodone Bitartrate | 53 | 26 |
| Morphine Sulfate Er | Morphine Sulfate | 53 | 24 |
| Novolog Flexpen | Insulin Aspart | 53 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 13 |
| Cephalexin | Cephalexin | 50 | 24 |
| Digoxin | Digoxin | 49 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | suppressed |
| Calcitriol | Calcitriol | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 36 |
| Montelukast Sodium | Montelukast Sodium | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 14 |
| Sucralfate | Sucralfate | 38 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | 21 |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 31 |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 16 |
| Movantik | Naloxegol Oxalate | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 23 |
| Diclofenac Potassium | Diclofenac Potassium | 28 | suppressed |
| Klor-Con 8 | Potassium Chloride | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Enulose | Lactulose | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | suppressed |
| Ursodiol | Ursodiol | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Paliperidone Er | Paliperidone | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | 11 |
| Klor-Con 10 | Potassium Chloride | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Olanzapine Odt | Olanzapine | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | suppressed |
| Buprenorphine | Buprenorphine | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Estradiol | Estradiol | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Acetazolamide Er | Acetazolamide | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Sotalol Af | Sotalol Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $244.63 · 5 records | Neurocrine BioSciences, Inc. | CAPLYTA, COBENFY, INGREZZA, REXULTI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error